Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04878691 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-04878691 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-04878691 3mg | DRUG | Oral solution, 3mg, twice weekly, 2 weeks |
| PF-04878691 6mg | DRUG | Oral solution, 6mg, twice weekly, 2 weeks |
| PF-04878691 9mg | DRUG | Oral solution, 9mg, twice weekly, 2 weeks |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18-55, inclusive. * Body Mass Index (BMI) of 18-30 kg/m2; total body weight \>50kg (110lbs). Exclusion Criteria: * Pregnant or nursing females. * Females of child-bearing potential. * Evidence of history of clinically s...
PF-04878691 is an investigational small molecule being developed for the treatment of Hepatitis C Virus (HCV). It is intended for use in infectious disease settings, targeting the viral infection. The drug is currently in clinical development, with studies evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in affected populations.
PF-04878691 is being developed by Pfizer, Inc., a multinational pharmaceutical company headquartered in the United States. Pfizer trades on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's potential as a treatment for Hepatitis C Virus.
PF-04878691 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under evaluation for its safety and pharmacological profile in the context of Hepatitis C Virus.
PF-04878691 has one completed clinical trial registered under NCT00810758. This Phase 1 study, titled "Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691," enrolled 24 participants in the United States. The trial was randomized and double-blind, though it did not use a control group.
PF-04878691 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial evaluated its safety and pharmacological properties in healthy volunteers, but the drug has not yet progressed through the later stages of clinical testing required for regulatory approval.